Indication
Post-ET Myelofibrosis
2 clinical trials
3 products
1 drug
Clinical trial
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibStatus: Recruiting, Estimated PCD: 2025-10-01
Product
TL-895Product
RuxolitinibClinical trial
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
NavtemadlinProduct
Navtemadlin